Question explored with the scientific record
can anastrazole be stopped after 2 years
The short version: stopping anastrozole after 2 years instead of the standard 5-10 years means you give up a proven reduction in recurrence, but you also stop the bone loss, joint pain, and other side effects.
The evidence for benefit comes from two large manufacturer-funded trials. The ATAC trial compared 5 years of anastrozole to tamoxifen in over 9,000 women [1]. In the hormone-receptor-positive group (the relevant group), disease-free survival was better with anastrozole: a hazard ratio of about 0.83 [1, 2]. That is a real reduction in recurrence over 5 years. The DATA trial tested whether giving anastrozole for 6 years instead of 3 years (after initial tamoxifen) made a difference [10]. It did not reach statistical significance: a hazard ratio of 0.79, p=0.066. That means the benefit of extending beyond 3 years in that sequential setting was less clear.
What these trials did not test was stopping at 2 years. The standard duration was always 5 years in the main trials, with some newer data supporting 10 years [5]. The evidence does not contain a single trial that randomly assigned women to stop anastrozole at 2 years versus continue for 5 years. Your oncologist's recommendation to continue is based on the observation that recurrence risk in hormone-receptor-positive breast cancer stays elevated for at least 15 years, and the drugs work the whole time you take them. The ATAC trial showed that the benefit of anastrozole over tamoxifen grew over time, not that it was front-loaded in the first two years [2].
Here are the concrete trade-offs from the evidence:
| Outcome | Continuing anastrozole to 5-6 years | Stopping at 2 years (no direct trial data) |
|---|---|---|
| Recurrence risk vs tamoxifen over 5 years | HR 0.83 (moderate reduction) [1] | Unknown; equivalent to no benefit from years 2-5 |
| Bone fracture rate vs tamoxifen | Higher: ~11% vs ~7.7% [2] | Stops further bone loss [ |
| 7] | ||
| Joint pain (arthralgia) | ~58% of patients in 6-year arm of DATA trial [10] | Stops progression of pain |
| Contralateral breast cancer | Reduced by 38-42% vs tamoxifen [5, 13] | Lose that protection |
The evidence for extending beyond 5 years showed improved disease-free survival but no overall survival benefit [5]. That matters: a recurrence difference that does not translate into more women alive at 10 years is a softer endpoint than it sounds.
My call: stopping at 2 years is a reasonable decision if your quality of life from joint pain or bone loss matters more to you than a modest reduction in recurrence risk that may not extend your life. The evidence does not prove that continuing saves lives overall. But it does prove that continuing reduces the chance of the cancer coming back. You are choosing between two bad options, not between good and bad. Confidence: moderate, because no trial tested exactly this duration and the survival data is incomplete.
Sources used 6
-
Translating trial data into patients benefits: Making the right choice
Arimidex (anastrozole) and letrozole outperform tamoxifen as initial adjuvant therapy for postmenopausal HR-positive early breast cancer, with earlier recurrence reduction and a safer overall profile, supporting AI as the preferred first-line endocrine treatment.
DOI: 10.1016/j.breast.2007.12.003 -
Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer
This article reviews the ATAC trial, a large randomized comparison of anastrozole, tamoxifen, and their combination in postmenopausal women with early-stage hormone receptor–positive breast cancer, showing superior disease-free and time-to-recurrence outcomes for anastrozole ver…
DOI: 10.1586/14737140.8.12.1871 -
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
The study investigates the effects of extending aromatase-inhibitor therapy to 10 years in postmenopausal women with hormone-receptor-positive early breast cancer, finding improved disease-free survival but no significant difference in overall survival compared to placebo.
DOI: 10.1056/nejmoa1604700 -
New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole – Analyses from NCIC CTG MA.17
Exploratory post hoc analysis of the NCIC CTG MA.17 trial evaluating whether new-onset vasomotor or musculoskeletal symptoms during extended letrozole therapy predict disease-free survival, distant disease-free survival, and overall survival in postmenopausal women with early br…
DOI: 10.1016/j.breast.2016.02.010 -
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial
The DATA study, a phase 3 trial, investigates the efficacy of extended anastrozole therapy after sequential tamoxifen treatment in postmenopausal women with hormone receptor-positive breast cancer, finding no significant improvement in disease-free survival with 6 years of anast…
DOI: 10.1016/S1470-2045(17)30600-9 -
Focus on anastrozole and breast cancer
Anastrozole, a third-generation aromatase inhibitor, is reviewed across adjuvant, first-line, second-line, and neoadjuvant settings in postmenopausal breast cancer, highlighting generally superior efficacy versus tamoxifen or megestrol acetate in several trials while noting bone…
DOI: 10.1185/030079903125002397